SCHEMBL1867971

SCHEMBL1867971

NC(CSCCC(=O)O)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BHMT Q93088 6/20 0.62
ARG1 P05089 1/20 0.62
ARG2 P78540 1/20 0.62
KMT2A Q03164 2/20 0.56
LMNA P02545 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
NOS2 P35228 3/20 0.55
NOS1 P29475 2/20 0.55
NOS3 P29474 1/20 0.55
GRM8 O00222 2/20 0.54
GRM6 O15303 2/20 0.54
GRM7 Q14831 2/20 0.54
GRM4 Q14833 2/20 0.54
GRIN2D O15399 1/20 0.54
GRIN3B O60391 1/20 0.54
GSR P00390 1/20 0.54
CYP1A2 P05177 1/20 0.54
GRIK1 P39086 1/20 0.54
GRM5 P41594 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1867969 1.00 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL7292563 0.90 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL7292565 0.90 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL15436097 0.90 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL17361240 0.88 ARG1 (0.69) BHMTARG1ARG2NOS2NOS1
SCHEMBL17361239 0.88 ARG1 (0.69) BHMTARG1ARG2NOS2NOS1
SCHEMBL6230471 0.88 BHMT (0.71) BHMTARG1ARG2KMT2ALMNA
SCHEMBL6230473 0.88 BHMT (0.71) BHMTARG1ARG2KMT2ALMNA
SCHEMBL1106818 0.84 ARG1 (0.60) BHMTARG1ARG2KMT2ANOS2
SCHEMBL4242586 0.84 ARG1 (0.60) BHMTARG1ARG2KMT2ANOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120936-B Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2024-06-25 CN claimed
CN-116120936-A Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2023-05-16 CN claimed
CN-114438190-A Opening and closing nerve soothing soup-autism core effect gene target and screening method thereof 中国人民解放军空军军医大学 2022-05-06 CN claimed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-02 US disclosed
WO-2025083208-A1 SYNTHESIS OF MORPHOLINE DERIVATIVES AND COMPOUNDS THEREFORE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-04-24 WO disclosed
US-20240366543-A1 METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA HEMOSHEAR THERAPEUTICS INC (US) 2024-11-07 US disclosed
CN-116120936-B Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2024-06-25 CN disclosed
EP-4319746-A1 METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA Hemoshear Therapeutics, Inc. (US) 2024-02-14 EP disclosed
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-02 US disclosed
WO-2023164127-A1 PET FOOD COMPOSITIONS AND METHODS FOR MODIFYING STOOL QUALITY MARS, INCORPORATED (US) 2023-08-31 WO disclosed
US-20090022862-A1 Method to limit acrylamide in heated foods CHILDREN'S MEDICAL CENTER CORPORATION (US) 2009-01-22 US disclosed
WO-2006017526-A2 METHOD TO LIMIT ACRYLAMIDE IN HEATED FOODS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2006-02-16 WO disclosed
CN-1479715-A Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils ��ķ�ɷ����޹�˾ 2004-03-03 CN disclosed
EP-0373339-B1 Silver halide recording material AGFA GEVAERT AG (DE) 1994-05-04 EP disclosed
US-5204326-A Analgesics, antiulcer agents, lowering calcium absorption OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-04-20 US disclosed
US-5089381-A SILVER HALIDE RECORDING MATERIAL AGFA-GEVAERT AG (DE) 1992-02-18 US disclosed
EP-0397985-A1 Polypeptide (calcitonin) derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-11-22 EP disclosed
EP-0373339-A1 Silver halide recording material Agfa-Gevaert AG (DE) 1990-06-20 EP disclosed
EP-0330241-A2 Calcitonin derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, PDGFRB, TEK BHMT 4465/4885ARG1 700/4885ARG2 1744/4885
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK BHMT 4465/4885ARG1 700/4885ARG2 1744/4885
US-20240366543-A1 METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA MMAB, OTC, ME2 BHMT 184/4885ARG1 1222/4885ARG2 351/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA BHMT 3732/4885ARG1 557/4885ARG2 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.